Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McNeil's OTC Nasalcrom rolling out in time for spring allergy season.

This article was originally published in The Tan Sheet

Executive Summary

McNEIL NASALCROM SPRAY FOR OTC ALLERGY PREVENTION AND RELIEF APPROVED, FDA informed the company in a Jan. 3 letter deeming the 4% cromolyn sodium nasal spray "safe and effective for use as an over-the-counter product for the prevention and relief of the nasal symptoms of hayfever and other nasal allergies in adults and in children six years of age and older." Nasalcrom will be on store shelves "in time for the spring allergy season," McNeil announced.

You may also be interested in...



Prestige Brands Is Up To New Devices With Allergen Block Launch

Prestige Brands is carving out a niche in the crowded OTC allergy market with the launch of Allergen Block - a drug-free gel that creates "an invisible shield" around the nose to stop allergens from entering nasal passages

Prestige Brands Is Up To New Devices With Allergen Block Launch

Prestige Brands is carving out a niche in the crowded OTC allergy market with the launch of Allergen Block - a drug-free gel that creates "an invisible shield" around the nose to stop allergens from entering nasal passages

Prestige Brands Is Up To New Devices With Allergen Block Launch

Prestige Brands is carving out a niche in the crowded OTC allergy market with the launch of Allergen Block - a drug-free gel that creates "an invisible shield" around the nose to stop allergens from entering nasal passages

Topics

UsernamePublicRestriction

Register

PS086563

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel